（无）

[1] RAO A, MOKA N,HAMSTRA DA, et al. Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now [J]. Cancers (Basel), 2022,14(3). 

[2] ROBINSON D,VAN ALLEN EM, WU YM,et al. Integrative clinical genomics of advanced prostate cancer [J]. Cell, 2015,161(5): 1215-1228. 

[3] CLARKENW,ARMSTRONGAJ,THIERY-VUILLEMINA, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer [J]. NEJM Evidence, 0(0): EVIDoa2200043. 

[4] CLARKENW,ARMSTRONGAJ,THIERY-VUILLEMINA, et al. Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (IL)therapy for metastatic castration- resistant prostate cancer(mCRPC)[J]. J Clin Oncol, 2023, 41(6-suppl): LBA16. 

[5] CHI KN,RATHKOPF DE,SMITH MR,et al. Phase 3 MAGNITUDE study: first results of niraparib(NIRA) with abiraterone acetate and prednisone(AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer(mCRPC)with and without homologous recombination repair(HRR) gene alterations [J]. J Clin Oncol, 2022,40(6-suppl): 12. 

[6] AGARWAL N,AZAD A,CARLES J, et al. TALAPRO-2: phase 3 study of talazoparib(TALA)+ enzalutamide (ENZA) versus placebo (PBO)+ ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer(mCRPC)[J]. J Clin Oncol, 2023, 41(6-suppl): LBA17. 

[7] CLINICAL TRIALS.GOV. A clinical study evaluating the benefit of adding rucaparib to enzalutamide for men with metastatic prostate cancer that has become resistant to testosterone-deprivation therapy [EB/OL].(2020-07-02)[2020-09-17]. https://clinicaltrials.gov/ct2/show/NCT04455750. 

[8] RAO A,RYAN CJ,VANDERWEELE DJ, et al. CASPAR(Alliance A031902): a randomized,phase Ⅲ trial of enzalutamide (ENZ) with rucaparib (RUCA)/ placebo(PBO)as a novel therapy in first- line metastatic castration-resistant prostate cancer (mCRPC)[J]. J Clin Oncol,2021,39(6-suppl): TPS181. 

[9] BRAY F,FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018,68(6): 394-424. 

[10] SIEGEL R,MA J, ZOU Z,et al. Cancer statistics, 2014 [J]. CA Cancer J Clin,2014,64(1): 9-29. 

[11] LI J,SIEGEL DA, KING JB. Stage-specific incidence rates and trends of prostate cancer by age,race,and ethnicity, United States, 2004-2014 [J]. Ann Epidemiol, 2018, 28(5): 328-330. 

[12] SAGARAM S, RAO A. Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer-a narrative review [J]. Transl Androl Urol, 2021,10(7): 3188-3198. 

[13] ANTONARAKIS ES, LU C, WANG H,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer [J]. N Engl J Med, 2014,371(11): 1028-1038. 

[14] CHENG HH,GULATI R,AZAD A,et al. Activity of enzalutamide in men with metastatic castration- resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel [J]. Prostate Cancer Prostatic Dis,2015, 18(2): 122-127. 

[15] CHI KN,ANNALA M,SUNDERLAND K,et al. A randomized phase Ⅱ cross-over study of abiraterone + prednisone(ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC)[J]. J Clin Oncol, 2017,35(15-suppl):5002. 

[16] DE BONO JS, CHOWDHURY S, FEYERABEND S, et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in Europe [J]. Eur Urol, 2018,74(1): 37-45. 

[17] BECKER DJ,IYENGAR AD,PUNEKAR SR,et al. Treatment of metastatic castration-resistant prostate cancer with abiraterone and enzalutamide despite PSA progression [J]. Anticancer Res, 2019,39(5): 2467-2473. 

[18] KHALAF DJ,ANNALA M,TAAVITSAINEN S,et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration- resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial [J]. Lancet Oncol, 2019,20(12):1730-1739. 

[19] TERADA N,MAUGHAN BL,AKAMATSU S,et al. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: the Kyoto- Baltimore collaboration [J]. Int J Urol, 2017,24(6): 441-448. 

[20] MORI K, KIMURA T,ONUMA H,et al. Lactate dehydrogenase predicts combined progression- free survival after sequential therapy with abiraterone and enzalutamide for patients with castration- resistant prostate cancer [J]. Prostate,2017,77(10): 1144-1150. 

[21] The molecular taxonomy of primary prostate cancer [J]. Cell,2015,163(4): 1011-1025. 

[22] ROBINSON DR,WU YM,LONIGRO RJ, et al. Integrative clinical genomics of metastatic cancer [J]. Nature,2017, 548(7667): 297-303. 

[23] BOYD LK, MAO X, LU YJ.The complexity of prostate cancer: genomic alterations and heterogeneity [J]. Nat Rev Urol, 2012,9(11): 652-664. 

[24] BOERRIGTER E,GROEN LN,VAN ERP NP,et al. Clinical utility of emerging biomarkers in prostate cancer iquid biopsies [J]. Expert Rev Mol Diagn, 2020,20(2): 219-230. 

[25] FIZAZI K,TRAN N,FEIN L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer [J]. N Engl J Med, 2017,377(4): 352-360. 

[26] BEER TM,ARMSTRONG AJ, RATHKOPF D,et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study [J]. Eur Urol,2017,71(2): 151- 154. 

[27] SMITH MR,SAAD F, CHOWDHURY S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer [J]. N Engl J Med, 2018,378(15): 1408-1418. 

[28] FIZAZI K, SHORE N, TAMMELA TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer [J]. N Engl J Med, 2019,380(13):1235-1246. 

[29] HUSSAIN M,FIZAZI K,SAAD F,et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer [J]. N Engl J Med,2018,378(26): 2465-2474. 

[30] MORRIS MJ,HELLER G,BRYCE AH,et al. Alliance A031201: a phase Ⅲ trial of enzalutamide (ENZ) versus enzalutamide,abiraterone,and prednisone (ENZ/AAP)for metastatic castration resistant prostate cancer (mCRPC)[J]. J Clin Oncol, 2019,37(15-suppl): 5008. 

[31] WANG X,YANG H, HU X,et al. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis [J]. J Oncol Pharm Pract,2021, 27(3): 614-622. 

[32] DEMIRCI A,BILIR C,GULBAGCI B,et al. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer [J]. Sci Rep, 2021,11(1): 14131. 

[33] HOUTGRAAF JH,VERSMISSEN J, VAN DER GIESSEN WJ. A concise review of DNA damage checkpoints and repair in mammalian cells [J]. Cardiovasc Revasc Med, 2006,7(3): 165-172. 

[34] REED E. DNA damage and repair in translational oncology: an overview [J]. Clin Cancer Res, 2010,16(18):4511-4516. 

[35] ViTOR AC,HUERTAS P,LEGUBE G,et al. Studying DNA double-strand break repair: an ever-growing toolbox [J]. Front Mol Biosci,2020,7; 24. 

[36] JUBIN T, KADAM A,JARIWALA M,et al. The PARP family: insights into functional aspects of poly (ADP- ribose) polymerase-1 in cell growth and survival [J]. Cell Prolif, 2016, 49(4): 421-437. 

[37] FARMER H, MCCABE N,LORD CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J]. Nature,2005,434(7035): 917-921. 

[38] BRYANT HE,SCHULTZ N, THOMAS HD,et al. Specific kiing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase [J]. Nature,2005,434(7035): 913-917. 

[39] LOTAN TL, KAUR HB, SALLES DC,et al. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer [J]. Mod Pathol,2021, 34(6): 1185-1193. 

[40] DE BONO J,MATEO J,FIZAZI K,et al. Olaparib for metastatic castration-resistant prostate cancer [J]. N Engl J Med,2020, 382(22): 2091-2102. 

[41] NICOLOSI P,LEDET E,YANG S,et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines [J]. JAMA Oncol,2019, 5(4): 523-528. 

[42] U.S. Food and Drug Administration. Rucaparib [EB/OL].(2017-05-18)[2018-03-14]. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm. 

[43] ABIDA W,CAMPBELL D,PATNAIK A, et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic eastrationresistant prostate cancer (mCRPC): updated analyses [J]. Ann Oncol,2019,30：v327-v328. 

[44] U.S. Food and Drug Administration. Full prescribing information for lynparza(olaparib)[EB/OL].(2014-12- 19)[2020-06-14].https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/208558s013lbl.pdf. 

[45] SMITH MR,SANDHU SK,KELLY WK,et al. Pre-specified interim analysis of GALAHAD: a phase Ⅱ study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer(mCRPC) and biallelic DNA-repair gene defects (DRD)[J]. Ann Oncol,2019,30: v884-v885. 

[46] DE BONO JS, MEHRA N, HIGANO CS, et al. TALAPRO-1: a phase Ⅱ study of talazoparib(TALA) in men with DNA damage repair mutations(DDRmut)and metastatic castration-resistant prostate cancer (mCRPC)-first interim analysis(IA)[J]. J Clin Oncol,2020,38(6-suppl): 119. 

[47] POLKINGHORN WR,PARKER JS,LEE MX,et al. Androgen receptor signaling regulates DNA repair in prostate cancers [J]. Cancer Discov, 2013,3(11): 1245-1253. 

[48] BIORENDER. DNA Repair Mechanisms [EB/OL].(2020)[2022- 01-23]. Https://App.Biorender.Com/Biorender-Templates. 

[49] ASIM M,TARISH F,ZECCHINI HI,et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer [J]. Nat Commun,2017,8(1): 374. 

[50] LI L, KARANIKA S, YANG G,et al. Androgen receptor inhibitor- induced "BRCAness" and PARP inhibition are synthetically lethal for castration- resistant prostate cancer [J]. Sci Signal,2017,10(480). 

[51] CHATTERJEE P,CHOUDHARY GS,ALSWILLAH T, et al. The TMPRSS2- ERG gene fusion blocks XRCC4- mediated nonhomologous end- joining repair and radiosensitizes prostate cancer cells to PARP inhibition [J]. Mol Cancer Ther, 2015,14(8):1896-1906. 

[52] BELTRAN H,WYATT AW,CHEDGY EC,et al. Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy [J]. Clin Cancer Res,2017, 23(22): 6802-6811. 

[53] GOODWIN JF,SCHIEWER MJ, DEAN JL,et al. A hormone-DNA repair circuit governs the response to genotoxic insult [J]. Cancer Discov, 2013,3(11): 1254-1271. 

[54] TA HQ,GIOELI D. The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer [J]. Endocr Relat Cancer, 2014, 21(5): R395-407. 

[55] CLARKE N,WIECHNO P,ALEKSEEV B,et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised,double-blind,placebo-controlled, phase 2 trial [J]. Lancet Oncol,2018,19(7): 975-986. 

[56] ASTRA ZENECA. A randomised, double-blind,placebo-controlled, multicentre phase Ⅲ study of olaparib plus abiraterone relative to placebo plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer (PROpel Study)2021 [EB/OL].(2018-10-31)[2020- 01-23].https://fdaaa.trialstracker.net/trial/NCT03732820/. 

[57] CHI KN,RATHKOPF DE,ATTARD G,et al. A phase ⅢI randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)[J]. J Clin Oncol,2020, 38(6-suppl): TPS257. 

[58] AGARWAL N, SHORE ND, DUNSHEE C, et al. TALAPRO-2: a placebo- controlled phase Ⅲ study of talazoparib(TALA) plus enzalutamide (ENZA) for patients with first- line metastatic castration- resistant prostate cancer(mCRPC)[J]. J Clin Oncol, 2020, 38(6-suppl): TPS264. 

[59] AGARWAL N,AZAD A,SHORE ND, et al.TALAPRO-2: a phase 3 randomized study of enzalutamide (ENZA)plus talazoparib(TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC)[J]. J Clin Oncol,2021, 39(15-suppl): TPS5089.

盛锡楠.《雄激素受体和PARP协同抑制作为前列腺癌新治疗模式的现况与进展》评论[J]. 泌尿外科杂志（电子版）,2023,15(3):10-17. DOI:10.20020/j.CNKI.1674-7410.2023.03.02

暂无相关信息！

暂无相关信息！

1 NHA单药治疗晚期前列腺癌的局限性

2 前列腺癌的DNA修复与同源重组修复基因突变

3 前列腺癌的PARP抑制剂单药治疗

4 AR和PARP协同抑制的合成致死率

    4.1 NHA和PARPi合成致死的临床研究数据总结

    4.2 正在进行的AR和PARPi联合治疗的临床研究——近期的研究重点和关键思考

5 总结

AR和PARP协同抑制诱导合成致死为联合用药治疗晚期前列腺癌开启了新的局面。与此同时，在早期疾病中，随着现有治疗方案越来越多的使用， 我们对新发或早期发病的NHA耐药性的了解也越来越深入。一些晚期前列腺癌患者迫切需要强化治疗，几项评估NHA和PARPi联合治疗疗效的临床研究正在进行中，并可能在不久的将来改变mCRPC患者的治疗格局。 

版权声明： 本文原文“Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now?",首次发表 在Cancers杂志，2022 Feb 4; 14(3):801.doi: 10.3390/cancers14030801;作者为：Arpit Rao, Nagaishwarya Moka, Daniel A Hamstra, Charles J Ryan。原文遵循CC BY 4.0协议(http:// creativecommons.org/licenses/by/4.0/)进行出版， 允许在标注署名的情况下对文章进行修改和分享， 本次二次发表不涉及一稿多投及侵犯版权等问题。 

致谢： 感谢默沙东(中国)投资有限公司张超和刘振华为本文摘译提供学术支持，感谢上海北翱医药科技有限公司为本文提供辅助编辑工作，感谢默沙东(中国)投资有限公司获得版权及发表的支持。

暂无相关信息！

暂无相关信息！